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1316Objective: The aim of this study was to evaluate the incidence, risk factors, and effect on outcomes of right
ventricular failure in a large population of patients implanted with continuous-flow left ventricular assist devices.
Methods: Patients (n ¼ 484) enrolled in the HeartMate II left ventricular assist device (Thoratec, Pleasanton,
Calif) bridge-to-transplantation clinical trial were examined for the occurrence of right ventricular failure. Right
ventricular failure was defined as requiring a right ventricular assist device, 14 or more days of inotropic support
after implantation, and/or inotropic support starting more than 14 days after implantation. Demographics, along
with clinical, laboratory, and hemodynamic data, were compared between patients with and without right ventric-
ular failure, and risk factors were identified.
Results: Overall, 30 (6%) patients receiving left ventricular assist devices required a right ventricular assist
device, 35 (7%) required extended inotropes, and 33 (7%) required late inotropes. A significantly greater percent-
age of patients without right ventricular failure survived to transplantation, recovery, or ongoing device support at
180 days compared with patients with right ventricular failure (89% vs 71%, P< .001). Multivariate analysis
revealed that a central venous pressure/pulmonary capillary wedge pressure ratio of greater than 0.63 (odds ratio,
2.3; 95% confidence interval, 1.2–4.3; P ¼ .009), need for preoperative ventilator support (odds ratio, 5.5; 95%
confidence interval, 2.3–13.2; P<.001), and blood urea nitrogen level of greater than 39 mg/dL (odds ratio, 2.1;
95% confidence interval, 1.1–4.1; P¼ .02) were independent predictors of right ventricular failure after left ven-
tricular assist device implantation.
Conclusions: The incidence of right ventricular failure in patients with a HeartMate II ventricular assist device is
comparable or less than that of patients with pulsatile-flow devices. Its occurrence is associated with worse out-
comes than seen in patients without right ventricular failure. Patients at risk for right ventricular failure might ben-
efit from preoperative optimization of right heart function or planned biventricular support. (J Thorac Cardiovasc
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The Journal of Thoracic and Cardiovascular Surinsufficient.1 Although cardiac transplantation remains an
attractive therapeutic option for select patients, only 2000
heart transplantations are performed each year in the United
States, largely as a result of donor shortages.2 This continued
limitation underscores the need for alternative avenues of
treatment for this patient cohort.
Mechanical circulatory support, and more specifically left
ventricular assist devices (LVADs), can be used in this set-
ting as a bridge to transplantation (BTT), as destination ther-
apy for patients who are not suitable for transplantation, and
as temporary support for patients whose cardiac function is
expected to recover. However, outcomes of patients are crit-
ically dependent on right ventricular (RV) function, which
must provide sufficient flow through the pulmonary vascula-
ture to fill the LVAD and ensure optimal performance. The
physiology of right ventricular failure (RVF) in patients with
LVADs has been evaluated previously, and the role of septal
position and movement secondary to LVAD assistance was
demonstrated as a potential mechanism for RVF, which isgery c May 2010
Abbreviations and Acronyms
BiVAD ¼ biventricular assist device
BTT ¼ bridge to transplantation
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Xcounterbalanced by significant reductions in RV afterload
and pulmonary pressures.3,4 However, these mechanisms
were derived mostly from the study of pulsatile LVADs,
and there is a question about whether these precepts are still
applicable for continuous-flow pumps.
The development of RVF in patients with an LVAD has
a direct effect on mortality and is associated with prolonged
length of intensive care unit and hospital stay.5-10 Patients
with severe RVF requiring biventricular assist devices (Bi-
VADs) have been shown to be more severely ill, with signif-
icantly higher preoperative creatinine levels, total bilirubin
levels, and need for intra-aortic balloon pump (IABP) support
than patients who were adequately supported with isolated
LVADs.11 Furthermore, RVF in patients with LVADs leads
to increased morbidity, including end-organ dysfunction,8,11
which can deteriorate further after LVAD implantation, re-
sulting in poor outcomes after cardiac transplantation.12
With proper identification of patients at high risk for RVF,
planned use of paracorporeal BiVADs might be appropriate
in such patients.13,14 Temporary right ventricular assist de-
vices (RVADs) can also be used in conjunction with chronic
LVADs for patients who are identified as only needing a few
days or weeks of RV support. Consequently, recent studies
have attempted to ascertain univariate,8,15 aswell asmultivar-
iate,16 predictors of RVF to identify patients at risk for RVF
after LVAD implantation. Preoperative identification of
such patients might help in pre-emptive placement of
RVADs, which could improve overall VAD outcomes.13
Most of the current studies describing RVF in patients
with LVADs are either limited by a small sample size or
a single-center experience or were done on earlier-genera-
tion pulsatile devices.8,9,15,17 The incidence of the need forThe Journal of Thoracic and CarRVADs and extended inotropic support have been published
for the initial HeartMate II (Thoratec, Pleasanton, Calif) trial
results.18,19 However, a detailed analysis of multicenter data
for the risks of RVF with the continuous-flow devices has
not been established for a large group of patients. The aim
of this study was to evaluate the incidence, risk factors,
and effect on outcomes of RVF in patients implanted with
the HeartMate II continuous-flow LVAD.
MATERIALS AND METHODS
Study Design
Data were analyzed from the multicenter HeartMate II pivotal clinical
trial for BTT. Details of the study design and trial results have been previ-
ously published for the initial 133 patients,18 and updated results have been
published for 281 patients.19 BetweenMarch 2005 and April 2008, the total
enrollment reached 484 patients at 36 centers, and these patients were in-
cluded in this analysis. Patients listed as status 1A or 1B on the heart trans-
plant list were implanted with the HeartMate II LVAD, and survival to
transplantation, actuarial survival, functional status, quality of life, and ad-
verse events were determined. All adverse events, including RVF, were ad-
judicated by an independent clinical events committee.
RVF was defined in the HeartMate II clinical trial as either the need for
an RVAD in addition to the LVAD (group 1), continuous inotropic support
for at least 14 days after implantation (group 2), or late inotropic support
starting 14 days after implantation (group 3). Data from groups 1 and 2
were combined to form an early RVF group, whereas group 3 patients
were examined separately (late RVF group). The rationale for differentiat-
ing early and late occurrences of RVF is that the cause of the RVF is likely
triggered by different mechanisms. Baseline preoperative demographic,
clinical, hemodynamic, and laboratory data were compared between pa-
tients with early RVF (groups 1 and 2) and patients without RVF to identify
potential predisposing risk factors. The effect of RVF on survival to trans-
plantation, recovery, or continuing support at 180 days after implantation
and on Kaplan–Meier actuarial survival was also determined.
Data analyzed included patients’ characteristics and demographics (age,
sex, cause of heart failure, and body surface area), baseline hemodynamics
(cardiac index, pulmonary capillary wedge pressure [PCWP], mean pulmo-
nary artery pressure, systolic pulmonary artery pressure, diastolic pulmo-
nary artery pressure, central venous pressure [CVP], CVP/PCWP ratio,20
right ventricular stroke work index [RVSWI], systolic blood pressure, left
ventricular ejection fraction, and left ventricular end-diastolic volume),
use of an IABP or ventilator support, laboratory data (blood urea nitrogen
[BUN], creatinine, alanine aminotransferase, total bilirubin, hematocrit,
white blood cell count [WBC], platelet count, and international normalized
ratio), and postoperative bleeding and transfusion requirements. The Uni-
versity of Michigan RVF risk score (MRVFRS) was calculated based on
the formula provided by Matthews and colleagues.16
Statistical Analysis
Differences between measures of continuous variables with and without
RVF were analyzed by using the independent-samples t test for normal data
and the Mann–Whitney U test for nonnormal data. For multiple groups
(no RVF vs RVF–RVAD [group 1] vs RVF–continuous inotropic support
for14 days after implantation [group 2] vs RVF–late inotropic support start-
ing 14days after implantation [group3]), single-factor analysis of variancewas
performed. When the residuals were not normally distributed, the Kruskal–
Wallis multiple-comparisons test was performed instead. For categoric
variables, Fisher’s exact test was used for comparing 2 groups, and Pearson’s
c2 test was used for more than 2 groups. All statistical comparisons were
2-sided. Univariate logistic regression was performed on all variables to iden-
tify the potential risk factors for earlyRVF, followed by stepwise forwardmul-
tivariate logistic regression on the univariate predictors, with an entry criteriondiovascular Surgery c Volume 139, Number 5 1317
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ical support was performed with the Kaplan–Meier method. Differences in
actuarial survival were evaluated by using the log-rank test. Patients were cen-
sored for transplantation, recovery of the native heart, andwithdrawal from the
study. All continuous parameters were first dichotomized at the 25th, 33rd,
50th, 66th, and 75th percentiles, and the percentile value with the lowest P
value was chosen as the threshold for the analysis. The dichotomization took
place at the 25th (BSA and hematocrit), 50th (mean pulmonary artery pressure
and systolic pulmonary artery pressure), 66th (CVP), and 75th (CVP/PCWP,
creatinine, BUN, AST, and WBC) percentiles. For RVSWI, the threshold
was set at 300mmHg$mL $m2,whichhas previously been shown tobe a crit-
ical value for RVAD implantation.21 The MRVFRS was dichotomized based
on the critical value previously proposed by Matthews and colleagues.16
Biochemical and hemodynamic variables are presented as means  standard
deviations, and categoric variables are presented as percentages. All statistical
analyses were done with SYSTAT (Cranes Software, Chicago, Ill).
RESULTS
Baseline Characteristics and RVF Incidence
Baseline data and comparisons between groups are sum-
marized in Table 1. A total of 98 (20%) of the 484 patientsTABLE 1. Preimplantation characteristics for all groups
RV
No RVF
(n ¼ 386)
RVF–RVAD
(n ¼ 30)
RVF–ear
(n
Percentage of total patients
(n ¼ 484)
80 6
Female sex 80 (21%) 7 (23%) 8 (
Ischemic cause 174 (45%) 15 (50%) 15 (
Age (y) 51.8  13.5 51.0  13.3 55.0
BSA 1.99  0.26 1.94  0.28 1.98
CI 2.1  0.7 2.0  0.6 2.2
PCWP (mm Hg) 25  8 26  8 26
PAPm (mm Hg) 36  9 35  9 35
PAPs (mm Hg) 52  13 49  12 50
PAPd (mm Hg) 27  8 27  8 26
CVP (mm Hg) 12.3  6.4 16.1  6.4y 14.5
CVP/PCWP ratio 0.51  0.46 0.64  0.21 0.57
RVSWI (mm Hg$mL $m2) 556  298 391  226* 541
PVR (Wood Units) 2.91  1.61 2.93  1.41 2.79
BPs (mm Hg) 99  16 102  18 98
Heart rate (beats/min) 91  19 98  19 89
IABP 161 (42%) 18 (60%) 15 (
Ventilatory support 21 (5%) 11 (37%)z 5 (
Pacing 188 (49%) 10 (33%) 20 (
Creatinine (mg/dL) 1.41  0.50 1.54  0.52 1.53
BUN (mg/dL) 29.6  16.6 36.1  17.5* 32.0
AST (mg/dL) 74  201 236  557y 78
TBILI (mg/dL) 1.25  0.78 1.39  1.43 1.34
HCT (%) 34.9  5.5 33.5  7.4 35.3
WBC (3103/mL) 8.7  3.6 11.2  4.6y 9.3
PLT (3103/mL) 226  88 221  90 220
INR (International Units) 1.32  0.33 1.57  1.01 1.35
MRVFRS 1.14  1.88 2.04  2.34 1.34
RVF, Right ventricular failure; RVAD, right ventricular assist device; BSA, body surface ar
monary artery pressure; PAPs, systolic pulmonary artery pressure; PAPd, diastolic pulmona
index; BPs, systolic blood pressure; IABP, intra-aortic balloon pump; BUN, blood urea nitr
white blood count; PLT, platelet count; INR, international normalized ratio;MRVFRS, Unive
compared with no-RVF group. xP value for differences between the 4 subgroups.
1318 The Journal of Thoracic and Cardiovascular Surhad some form of RVF according to trial definitions. This in-
cluded 30 (6%) patients requiring an RVAD (group 1), 35
(7%) patients requiring at least 14 days of continuous ino-
tropic support after implantation (group 2), and 33 (7%) pa-
tients requiring late inotropic support starting after the 14th
day (group 3). Demographic and hemodynamic data were
typical of patients with advanced heart failure and were sim-
ilar between patients with early RVF and patients without
RVF, with the following notable exceptions: baseline CVP
was significantly higher in patients with early RVF (15.0
 7.0 mm Hg), especially for patients requiring RVADs
(16.1  6.4 mm Hg), when compared with those without
RVF (12.3  6.4 mm Hg, P ¼ .002). Similarly, the CVP/
PCWP ratio was significantly higher for the early RVF
groups compared with the no-RVF group (0.60  0.20 vs
0.51  0.46), and mean RVSWI was significantly lower
for the early RVF group (477  306 vs 556  298 mm
Hg$mL1$m2, P ¼ .03). Furthermore, more than 30% ofF subgroups
ly inotropes
¼ 35)
RVF–late inotropes
(n ¼ 33) P valuex
Any early RVF
(n ¼ 65)
7 7  13
23%) 13 (39%) .1 15 (23%)
43%) 10 (30%) .37 30 (46%)
 11.0 48.6  12.0 .12 53.0  12.0
 0.30 2.11  0.63 .58 1.96  0.29
 0.8 2.0  0.5 .96 2.1  0.7
 8 24  7 .6 26  6
 9 35  11 .94 35  9
 16 50  17 .54 50  14
 8 26  9 .87 27  8
 7.1* 12.9  7.7 .01 15.2  6.8y
 0.27 0.51  0.23 .1 0.60  0.20z
 344.1 560  335 .04 477  306*
 1.55 2.94  1.67 .97 2.85  1.48
 15 95  14 .51 100  16
 17 87  19 .14 93  18
43%) 9 (27%) .07 33 (51%)
14%)* 3 (9%) <.001 16 (25%)z
57%) 18 (55%) .23 30 (46%)
 0.59 1.47  0.63 .34 1.53  0.56
 13.6 33.1  19.7 .05 33.8  15.0*
 236 89  164* .02 148  415
 0.71 1.25  0.98 .55 1.36  1.07
 6.0 34.5  5.4 .26 4.5  6.6
 3.2 8.4  3.2 .01 10.1  4.0y
 74 225  93 .98 220  81
 0.32 1.37  0.44 .89 1.5  0.71
 1.70 1.38  1.80 .08 1.65  2.00*
ea; CI, cardiac index; PCWP, pulmonary capillary wedge pressure; PAPm, mean pul-
ry artery pressure; CVP, central venous pressure; RVSWI, right ventricular stroke work
ogen; AST, aspartate aminotransferase; TBILI, total bilirubin; HCT, hematocrit; WBC,
rsity of Michigan right ventricular failure risk score. *P<.05, yP<.01, and zP<.001
gery c May 2010
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had an RVSWI of less than 300 mm Hg$mL $m2 compared
with 16% of patients without RVF.
For baseline laboratory data, preoperative WBC (10.1 
4.0 vs 8.7  3.6 3 103/mL, P ¼ .004) and BUN (33.8 
15.0 vs 29.6  16.6 mg/dL, P ¼ .01) values were signifi-
cantly higher for those with early RVF compared with
values in those without RVF (Table 1). These values were
further increased for patients requiring an RVAD, in
whom the WBC (11.2  4.6 vs 8.7  3.6 3 103/mL, P<
.05) and BUN (36.1  17.5 vs 29.6  16.6, P< .05) values
were significantly higher than those in patients with no RVF.
A significantly higher proportion of the few patients (n ¼
40) on ventilator support before HeartMate II implantation
had early RVF compared with those who were not (40%
vs 11%, P< .001), 28% of whom required an RVAD. Fi-
nally, the AST value was significantly higher in those requir-
ing an RVAD compared with that seen in those who did not
have RVF (236 557 v 74 201 mg/dL, P<.03). Patients
with early RVF had a higher MRVFRS (1.65 2.00 vs 1.14
 1.88, P<.02), whereas there was no significant difference
between the corresponding RVF subgroups.
Of the patients who were started on an RVAD, 14 re-
ceived a Centrimag (Levitronix,Waltham,Mass), 9 received
an Abiomed (Abiomed, Danvers, Mass), 3 received a Tan-
dem Heart (Cardiac Assist, Pittsburgh, Pa), and 4 received
a Thoratec paracorporeal VAD (Thoratec, Pleasanton, Calif)
(Table 2). Most RVADs were implanted within the first 24
hours of LVAD surgery. Eight patients received an RVAD
after 24 hours, with 1 patient receiving an RVAD 38 days
after LVAD surgery. Three of these 8 patients underwent
transplantation, 4 died, and 1 was withdrawn. Durations of
support for all RVADs ranged from 0 to 408 days.
Clinical Outcome
In patients without RVF, 342 (89%) survived to trans-
plantation, recovery, or continuing support at 180 days
(Table 3). Patients with early RVF had significantly worse
survival to the same end points (n ¼ 46, 71%; P ¼ .001),
with those requiring RVADs having the lowest percentage
reaching these outcomes (n ¼ 20, 67%; P< .001). Within
the RVAD group, 17 (77%) of 22 patients who received
an RVAD within the first 24 hours survived to the primaryTABLE 2. Patients requiring RVADs
No. Day implanted*
RVADs
Centrimag 14 0 (0–2)
Paracoporeal VAD 4 2 (0–15)
Abiomed 9 0 (0–10)
Tandem Heart 3 0 (0–38)
Total 30 0 (0–38)
RVADs, Right ventricular assist devices. *Median and ranges.
The Journal of Thoracic and Caroutcome at 180 days, whereas only 3 (39%) of 8 patients
who received an RVAD later survived to the same end point.
Actuarial survival at 1 year was also significantly better for
patients without RVF (79%) compared with that in patients
requiring RVADs (group 1, 59%; P ¼ .004) or extended
inotropes (group 2, 56%; P ¼ .007), whereas there was no
difference for patients with late inotrope use (group 3,
75%; P ¼ .81). Decreased survival for patients with early
RVF is evident in the grouped Kaplan–Meier survival curve
(Figure 1).
Hospital length of stay for discharged patients was longer
for those requiring an RVAD than for those without RVF
(32 vs 22 days, P<.001). Those who required inotropic sup-
port for more than 14 days after LVAD implantation and
those with late inotropic support had an average length of
stay of 35 and 32 days, respectively. Thus any RVF resulted
in a significantly longer hospitalization time before dis-
charge than seen in those without any RVF (P< .001).
Univariate and Multivariate Preoperative Risk
Factors
Univariate analyses of predictors of RVF are shown in Ta-
ble 4, and the associated relative risk ratios are depicted in
Figure 2. The hemodynamic variables of CVP greater than
15 mm Hg, RVSWI less than 300 mm Hg$mL$m2, and
aCVP/PCWP ratio greater than 0.63were statistically signif-
icant predictors that indicated a higher risk of RVF. There
were no statistically significant differences in pulmonary ar-
tery pressures or pulmonary vascular resistance between
groups. With a baseline CVP of greater than 15 mm Hg,
19% of patients had early RVF compared with 10% of pa-
tients with a CVP of less than 15 mm Hg (odds ratio [OR],
2.1; 95% confidence interval [CI], 1.2–3.6; P< .01). Simi-
larly 22% of patients with a CVP/PCWP ratio of greater
than 0.63 had early RVF compared with 11% with a CVP/
PCWP ratio of less than 0.63, and 26% of patients with an
RVSWI of less than 300 mm Hg$mL$m2 had RVF com-
pared with 10% of patients with an RVSWI of greater than
300 mm Hg$mL$m2. Increased WBC and lower hematocrit
values were also statistically significant between those who
required RVAD support and those who did not. Patients on
preoperative ventilator support were 5 times more likely to
have RVF compared with those without ventilator support.Duration of use (d)
Outcome: transplanted or
ongoing support at 180 d
17 (6–148) 79%
8 (0–50) 75%
5 (0–408) 44%
25 (7–106) 66%
13 (0–408) 67%
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TABLE 3. Outcomes
Patients (n ¼ 484)
Length of stay for
discharged patients (d)
Transplant, recovery,
or ongoing at 180 d
Kaplan–Meier
survival at 1 y
No RVF 386 (80%) 22 (8–180) 342 (89%) 78%  3%
RVF subgroups
RVAD 30 (6%) 32 (0–158)z 20 (67%)y 59%  9%y
Inotropes, early 35 (7%) 35 (17–73)z 25 (71%)* 56%  9%y
Inotropes, late 33 (7%) 32 (12–86)z 29 (88%) 75%  9%
Any early RVF 65 (13%) 32 (0–173)z 46 (71%)z 59%  7%y
RVF, Right ventricular failure; RVAD, right ventricular assist device. *P< .05, yP< .01, and zP< .001 compared with the no-RVF group.
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XIncreasedMRVFRSs, creatinine values, or AST values were
not statistically significant predictors of RVF.
Multivariate analysis revealed that a CVP/PCWP ratio of
greater than 0.63 (OR, 2.3; 95% CI, 1.2–4.3; P< .009]),
need for ventilatory support (OR, 5.5; 95% CI, 2.3–13.2;
P< .001), and a preoperative BUN value of greater than
39 mg/dL (OR, 2.1; 95% CI, 1.1–4.1; P<.02) were the sig-
nificant independent preoperative predictors of early RVF
after LVAD implantation. The area under the receiver oper-
ating curve was 0.68, which is comparable with that seen in
earlier risk models of RVF.16Intraoperative and Postoperative Factors
There were no significant differences in bleeding and
transfusion requirements during implantation or within the
first 48 hours of LVAD implantation (Table 5) for those
who eventually had RVF. However, patients implanted
with an RVAD required a greater number of units of packed
red blood cell transfusions compared with those without
RVF (14.3  18.9 vs 5.6  5.8 units, P<.03) and more of-
ten required a reoperation for bleeding (40% vs 19%, P<
.04). Fifty-three percent of patients who needed an RVAD
required greater than 6 units of packed red blood cells duringFIGURE 1. Kaplan–Meier survival for patients with and without early
RVF receiving the HeartMate II LVAD, which includes the need for
RVADs or extended inotropic support for more than 14 days.
1320 The Journal of Thoracic and Cardiovascular Surthe implantation procedure, whereas only 26% of those
without RVF required similar levels of transfusion. Cardio-
pulmonary bypass times were higher in those who required
an RVAD (149 76 vs 106 61 minutes, P<.005), which
is likely attributable to the additional surgical procedures re-
quired to implant an RVAD.
DISCUSSION
Patients receiving the HeartMate II continuous-flow
LVAD as a BTT demonstrated a 6% incidence of RVF re-
quiring an RVAD and a 7% incidence of extended inotropic
support, for an overall incidence of early RVF of 13%. Pa-
tients receiving the HeartMate II with early RVF had a 20%
reduction in 1-year survival compared with that seen in pa-
tients who did not have RVF. In addition, patients requiring
inotropic agents starting 14 days after LVAD implantation
did not have a reduction in survival, although their length
of hospital stay was increased. The overall incidence of early
RVF seems to have decreased from those reported previ-
ously,8,9,11 which can be attributed to the improved patient
selection and optimization of the right heart before LVAD
implantation. The presence of RVF of any sort was associ-
ated with longer cardiopulmonary bypass times during sur-
gical intervention and the subsequent need for blood
transfusions, with the highest values in patients requiring
an RVAD. RVSWI, increased preimplantation CVP, in-
creased preimplantation CVP/PCWP ratio, and impaired re-
nal or respiratory function also appear to predispose to the
need for an RVAD after LVAD implantation.
Several previous studies have attempted to understand the
mechanism leading to RVF in LVAD recipients, and numer-
ous conflicting reports contest to the complex host of vari-
ables at play in this setting. One of the more common
explanations is that the acute unloading of the left heart ven-
tricle leads to a septal shift that alters RV shape and size,
thereby affecting its contractility.3,4,22 In addition, pre-exist-
ing RV impairment might be unmasked with the increase in
right-sided preload afforded by LVAD perfusion.4,8 These
aspects are now being routinely considered at the time of
LVAD and when deciding on device settings to keep the
septal shift to a minimum.
There is a common misconception that the reduced sur-
vival rate in patients requiring biventricular support is duegery c May 2010
TABLE 4. Univariate predictors of RVF
RVF subgroups
No RVF RVF–RVAD
RVF–early
inotropes
RVF–late
inotropes Any early RVF Odds ratios
Female sex (n ¼ 108) 80 (74%) 7 (6%) 8 (7%) 13 (12%) 15 (13%) 1.15 (0.60–2.20)*
Male sex (n ¼ 376) 306 (81%) 23 (6%) 27 (7%) 20 (5%) 50 (13%)
BSA>1.8 (n ¼ 351) 286 (82%) 20 (6%) 22 (6%) 23 (6%) 42 (12%) 1.56 (0.90–2.70)*
BSA 1.8 (n ¼ 133) 100 (75%) 10 (7.5%) 13 (10%) 10 (7.5%) 23 (17%)
PAPm>36 mm Hg (n ¼ 217) 181 (83%) 8 (4%) 14 (6%) 14 (6%) 22 (10%) 1.7 (1.00–3.00)*
PAPm 36 mm Hg (n ¼ 261) 205 (77%) 22 (8%) 21 (8%) 19 (7%) 43 (16%)
PAPs>52 mm Hg (n ¼ 221) 185 (84%) 10 (5%) 13 (6%) 13 (6%) 23 (10%) 1.7 (0.97– 2.90)
PAPs 52 mm Hg (n ¼ 263) 201 (76%) 20 (8%) 22 (8%) 20 (8%) 42 (16%)
CVP>15 mm Hg (n ¼ 176) 129 (73%) 16 (9%)y 17 (10%) 14 (8%) 33 (19%)z 2.1 (1.20–3.60)
CVP 15 mm Hg (n ¼ 282) 236 (84%) 12 (4%) 17 (6%) 17 (6%) 29 (10%)
CVP/PCWP>0.63 (n ¼ 98) 67 (68%) 10 (10%)y 12 (12%)y 9 (9%) 22 (22%)z 2.5 (1.37–4.60)*
CVP/PCWP 0.63 (n ¼ 302) 251 (83%) 14 (5%) 19 (6%) 18 (6%) 33 (11%)
RVSWI>300 mm
Hg$mL$m2 (n ¼ 347)
285 (82%) 11 (3%) 25 (7%) 26 (7%) 36 (10%) 2.9 (1.60–5.30)
RVSWI 300 mm
Hg$mL$m2 (n ¼ 78)
55 (70%) 13 (17%)z 7 (9%) 3 (4%) 20 (26%)x
Ventilatory Support
(þ) (n ¼ 40)
21 (52.5%) 11 (28%)z 5 (12.5%)z 3 (7.5%) 16 (40%)x 5.7 (2.80–11.60)*
Ventilatory Support
() (n ¼ 444)
365 (82.2%) 19 (4%) 30 (7%) 30 (7%) 49 (11%)
Creatinine>1.7 mg/dL
(n ¼ 118)
88 (75%) 10 (8%) 11 (9%) 9 (8%) 21 (18%) 1.6 (0.90–2.90)*
Creatinine 1.7 mg/dL
(n ¼ 366)
298 (81%) 20 (5%) 24 (7%) 24 (7%) 44 (12%)
BUN>39 mg/dL (n ¼ 118) 87 (74%) 11 (9%) 11 (9%) 9 (8%) 22 (19%)y 1.7 (1.00–3.10)*
BUN 39 mg/dL (n ¼ 366) 299 (82%) 19 (5%) 24 (7%) 24 (7%) 42 (12%)
AST>49 mg/dL (n ¼ 118) 88 (74.6%) 14 (12%)y 8 (7%) 8 (7%) 22 (19%) 1.73 (0.98–3.00)*
AST 49 mg/dL (n ¼ 366) 298 (81%) 16 (4%) 27 (7%) 25 (7%) 43 (12%)
HCT>31% (n ¼ 353) 290 (82%) 13 (4%) 24 (7%) 26 (7%) 37 (10%) 2.3 (1.30–3.90)
HCT 31% (n ¼ 131) 96 (73%) 17 (13%)x 11 (8%) 7 (5%) 28 (21%)z
WBC>10.4 3 103/mL
(n ¼ 120)
87 (73%) 15 (13%) 10 (8%) 8 (7%) 25 (21%) 2.2 (1.20–3.70)*
WBC 10.4 3 103/mL
(n ¼ 364)
299 (82%) 15 (4%)x 25 (7%) 25 (7%) 40 (11%)z
MRVFRS 5.5 (n ¼ 22) 18 (82%) 3 (14%) 0 (0%) 1 (5%) 3 (14%) 0.99 (0.28–3.50)
MRVFRS<5.5 (n ¼ 462) 368 (80%) 27 (6%) 35 (8%) 32 (7%) 62 (14%)
RVF, Right ventricular failure; RVAD, right ventricular assist device; BSA, body surface area; PAPm, mean pulmonary artery pressure; PAPs, systolic pulmonary artery pressure;
CVP, central venous pressure; PCWP, pulmonary capillary wedge pressure; RVSWI, right ventricular stroke work index; BUN, blood urea nitrogen; AST, aspartate aminotransfer-
ase;HCT, hematocrit;WBC, white blood count;MRVFRS, University of Michigan right ventricular failure risk score. *Parameters entered into the multivariate model. yP<.05, zP
< .01, and xP< .001 compared with the no-RVF group.
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Xto the BiVADs themselves. However, there is ample evi-
dence that the same preoperative risk factors that predispose
a patient to RVF are also risk factors for mortality after
LVAD support. In more recent studies, laboratory variables
associated with pre-LVAD severity of illness, which are in-
directly related to RV function (eg, bilirubin, creatinine, ven-
tilatory support, and IABP use) were found to be more
strongly associated with the need for biventricular support
as opposed to preimplantation hemodynamic vari-
ables.11,16,23 These variables might be influencing the pre-
disposition to perioperative bleeding, which negatively
affects pulmonary flow because of the interstitial edema as-The Journal of Thoracic and Carsociated with blood transfusion and lung damage. In another
analysis of 245 patients, the need for pre-LVAD circulatory
support, female sex, and nonischemic cause were found to
independently predict RVF after LVAD placement.9 A
more recent study evaluating preoperative RV geometry
and tricuspid incompetence found these factors to reliably
predict RVF in LVAD recipients.24 However, limitations,
such as small sample sizes, single-center nature, and pump
type, have precluded these findings from being applicable
to patients implanted with newer continuous-flow devices.
This report is the largest to date analyzing the effect of
continuous-flow LVADs on RV function. The primarydiovascular Surgery c Volume 139, Number 5 1321
FIGURE 2. Relative risk ratios of univariate and multivariate predictors of RVF during LVAD support.
Cardiothoracic Transplantation Kormos et al
T
Xfinding was that a combination of hemodynamic and clinical
variables can be used to identify patients who might be at
high risk for RVF. A high preoperative WBC, BUN value,
and preoperative ventilatory support, along with increased
CVP, CVP/PCWP ratio, and decreased RVSWI, were found
to be significant univariate predictors of RVF. High CVP
and low RVSWI before LVAD implantation can be associ-
ated with 2 conditions: worsening right heart function as a re-
sult of increased left-sided filling pressures and thus
pulmonary hypertension (group A) and intrinsic right heartTABLE 5. Intraoperative and postoperative characteristics
RVF
No RVF
(n ¼ 386)
RVF–RVAD
(n ¼ 30)
RVF–early
(n ¼
Percentage of total
patients (n ¼ 484)
80 6 7
Reoperation for bleeding* 72 (19%) 12 (40%)y 7 (20
Bleeding>2 units
during implantation
269 (70%) 25 (83%) 21 (60
Bleeding>6 units
during implantation
102 (26%) 16 (53%)y 7 (20
Bleeding>2 units<48 h 207 (54%) 15 (52%) 15 (43
Bleeding>6 units<48 h 110 (29%) 9 (31%) 7 (20
PRBC during<48 h 5.5  5.8 14.3  18.9* 4.8 
Cardiopulmonary bypass
time (min)
106  61 149  76z 101 
RVF, Right ventricular failure; RVAD, right ventricular assist device; PRBC, packed red bloo
for differences between the 4 subgroups.
1322 The Journal of Thoracic and Cardiovascular Surdysfunction as a result of a progressive myopathic process
(group B). The CVP/PCWP ratio was used to better differen-
tiate between patients who fall in group A from those in
group B. Hence those with right-sided dysfunction as a result
of persistently high left-sided filling pressure would have
a low CVP/PCWP ratio, and those with intrinsic RV dys-
function would have a high CVP/PCWP ratio. A CVP/
PCWP ratio of greater than 0.63, which represents the
75th percentile of values in the overall population, was in
fact an independent multivariate risk factor for RVF, andsubgroups
inotropes
35)
RVF–late inotropes
(n ¼ 33) P valuex
Any early RVF
(n ¼ 65)
7  13
%) 9 (27%) .03 19 (29%)*
%) 20 (61%) .15 46 (71%)
%) 8 (24%) .01 13 (20%)
%) 12 (38%) .19 30 (46%)
%) 6 (19%) .44 16 (25%)
4.8 5.1  5.7 .04 8.8  13.9
41 99  40 .004 124  64*
d cells. *P<.05, yP<.01, and zP<.001 compared with the no-RVF group. xP value
gery c May 2010
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Xnotably, CVP was not. Thus patients with a CVP that ap-
proaches the left-sided filling pressure before LVAD might
represent the group at highest risk for right heart failure after
LVAD implantation. In addition, those who have a lack of
RV contractile reserve and have a relatively greater increase
of right-sided filling pressures might have more septal shift
and increased venous return, which outweighs any benefits
of left ventricular unloading. Identifying such risk factors
is clinically relevant because it might help in selecting pa-
tients who will benefit from biventricular rather than univen-
tricular support. This is especially important because recent
studies have shown that a planned placement of biventricu-
lar support results in superior outcomes compared with de-
layed conversion of LVADs to biventricular support.13
Preoperative optimization strategies can also help the right
ventricle, for example by reducing the volume status as
much as possible before the LVAD implantation.
Although the incidence of RVAD insertion in LVAD recip-
ients has been decreasing as clinical experience with RVF
management accumulates, the mortality associated with
RVF remains high.5–7,25 Moreover, this increased mortality
is a direct result of RVF leading to less flow to the LVAD
and therefore less pump output and increased venous pressure
leading to decreased perfusion to vital organs. The findings of
the current study were similar to those of these prior studies in
that patients with RVF experienced a lower survival rate to
transplantation, recovery, or continuing support at 180 days.
These observations again reiterate the need for better selection
of patients at high risk for RVF, which might help in prevent-
ing its occurrence by providing mechanical assistance to the
right side simultaneously with LVAD implantation, as evi-
dencedby improved180-day survival inpatientswho received
an RVAD within 24 hours of LVAD surgery.
Limitations of this study include its retrospective nature
because of which there was no concurrent control group for
comparison with pulsatile devices. Results from a random-
ized comparison of pulsatile and continuous-flow devices
will be available at the conclusion of the HeartMate II Desti-
nation Therapy clinical trial. Although RVF was comprised
of 3 groups, the early inotrope (group 2) and RVAD (group
1) groups exhibited similar survival characteristics, whereas
the late inotrope group (group 3) resembled the no-RVF
group. For this reason, the late inotrope group (group 3)
was excluded from the RVF group for most of the analyses
but should be the focus of future studies.
In conclusion, rates of RVF and RVAD requirement in
patients with the HeartMate II are low relative to previous
results with pulsatile LVADs and support the use of this de-
vice in those with end-stage heart failure. Nevertheless, the
development of RVF remains difficult to predict, although
our data suggest that both clinical and hemodynamic factors
affect the development of RVF. RVF in HeartMate II recip-
ients is associated with worse clinical outcomes than in pa-
tients without RVF, which underscores the importance ofThe Journal of Thoracic and Carappropriate RVF management and prevention in this patient
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